Shire Files Lawsuit Against Watson Pharmaceuticals, Inc. for Infringement of ADDERALL XR(R) Patents and for Breach of Contract

By Shire Plc, PRNE
Tuesday, April 5, 2011

DUBLIN and PHILADELPHIA, April 6, 2011 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, announces that its subsidiary Shire LLC has filed
a lawsuit in the U.S. District Court for the Southern District of New York
against Watson Pharmaceuticals, Inc. and its subsidiaries Watson
Laboratories, Inc.-Florida, Watson Pharma, Inc., Andrx Corporation, and Andrx
Pharmaceuticals, L.L.C. for infringement of Shire's U.S. Reissue Patent No.
RE 41,148, U.S. Reissue Patent No. RE 42,096 and U.S. Patent No. 6,913,768
and also for breach of contract.

The lawsuit results from an Abbreviated New Drug Application (ANDA)
recently filed by Watson for generic versions of 5 mg, 10 mg, 15 mg, 20 mg,
25 mg and 30 mg ADDERALL XR, pursuant to which Watson provided notice that it
would seek to market its generic products before the expiration of Shire's
patents. The lawsuit alleges that all of Watson's generic strengths infringe
the patents-in-suit. Pursuant to Hatch-Waxman legislation, there will be up
to a 30-month stay with respect to Watson's proposed generic products. The
lawsuit also alleges that Watson has violated existing settlement and license
agreements between Shire and Watson, signed in November 2007, arising from an
ANDA that Watson filed in 2006, which also sought approval to market generic
versions of ADDERALL XR.

Shire submitted a Citizen Petition (CP) to the FDA in October 2005
requesting that the FDA impose stricter bioequivalence standards before
approving any ANDA for ADDERALL XR. The FDA responded that the CP raised
"complex issues" and has not resolved the matter. The FDA has not approved

Notes to editors


Shire's strategic goal is to become the leading specialty
biopharmaceutical company that focuses on meeting the needs of the specialist
physician. Shire focuses its business on attention deficit hyperactivity
disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI)
diseases as well as opportunities in other therapeutic areas to the extent
they arise through acquisitions. Shire's in-licensing, merger and acquisition
efforts are focused on products in specialist markets with strong
intellectual property protection and global rights. Shire believes that a
carefully selected and balanced portfolio of products with strategically
aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website:

ACT OF 1995

Statements included herein that are not historical facts are
forward-looking statements. Such forward-looking statements involve a number
of risks and uncertainties and are subject to change at any time. In the
event such risks or uncertainties materialize, the Company's results could be
materially adversely affected. The risks and uncertainties include, but are
not limited to, risks associated with: the inherent uncertainty of research,
development, approval, reimbursement, manufacturing and commercialization of
the Company's Specialty Pharmaceutical and Human Genetic Therapies products,
as well as the ability to secure and integrate new products for
commercialization and/or development; government regulation of the Company's
products; the Company's ability to manufacture its products in sufficient
quantities to meet demand; the impact of competitive therapies on the
Company's products; the Company's ability to register, maintain and enforce
patents and other intellectual property rights relating to its products; the
Company's ability to obtain and maintain government and other third-party
reimbursement for its products; and other risks and uncertainties detailed
from time to time in the Company's filings with the Securities and Exchange

    For further information please contact:

    Investor Relations  Eric Rojas (        +1-781-482-0999

    Media               Jessica Mann (       +44-1256-894-280
                        Matthew Cabrey (   +1-484-595-8248

For further information please contact: Investor Relations Eric Rojas (erojas at +1-781-482-0999; Media: Jessica Mann (jmann at +44-1256-894-280; Matthew Cabrey (mcabrey at +1-484-595-8248

Pharmaceuticals News

April 6 News

will not be displayed